6
304
R. Ramachandran et al. / Bioorg. Med. Chem. Lett. 21 (2011) 6301–6304
inhibition activity by four and two fold against B. subtilis and
K. pneumonia, respectively, and moderate activity (50 g/mL) was
observed against E. coli and S. typhi. Similarly, introduction of fluoro
those with fluoro function at C-2 and C-4 phenyl group exerted
highest level of antibacterial and antifungal activities. Thus, in fu-
ture, this class of thiazoles derivatives may be used as templates to
generate better drugs to fight bacterial and fungal infections.
l
function at the meta position of the 2,4-diphenylpiperidine ring
(
compound 3c), demonstrated significant inhibition growth at
2.5 g/mL against S. aureus but against B. subtilis did not showed
bacterial activity even at maximum concentration (200 g/mL).
1
l
Supplementary data
l
The replacement of para fluorophenyl group (compound 3b) by
para chlorophenyl group (compound 3d) decreases the inhibition
activity against all the tested bacterial strains. Modification of po-
sition of chloro function from para to ortho in 2,4-diphenylpiperi-
dine ring (compound 3e) registered a significant activity against
Supplementary data (the detailed experimental and spectral
data (IR, H NMR and C NMR) for all the synthesized compounds
1
13
(
E. coli (6.25 lg/mL) and B. subtilis (12.5 lg/mL). Moreover, the ob-
References and notes
served activity (compound 3e against E. coli) is one fold higher than
that of the standard drug (Streptomycin). Electron withdrawing
substituents like fluoro and chloro substituted 2,4-diarylpiperi-
1. (a) Hoefle, G.; Bedorf, N.; Gerth, K.; Reichenbach, H. Ger. Offen. DE 4138042 A1
1
9930527, 1993.; (b) Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.;
Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Cancer Res. 1995, 55,
325.
dines or 2,4-disubstituted piperidine derivatives exerted excellent
2
antibacterial and antifungal activities.2
1,23
Fluorination increases
2. (a) Ojika, M.; Suzuki, Y.; Tsukamoto, A.; Sakagami, Y.; Fudou, R.; Yoshimura, T.;
Yamanaka, S. J. Antibiot. 1998, 51, 275; (b) Suzuki, Y.; Ojika, M.; Sakagami, Y.;
Fudou, R.; Yamanaka, S. Tetrahedron 1998, 54, 11399; (c) Riego, E.; Hernández,
D.; Albericio, F.; Álvarez, M. Synthesis 2005, 1907.
the lipophilicity due to strong electron withdrawing capability of
2
6
fluorine. Moreover, fluorine substitution was commonly used in
contemporary medicinal chemistry to improve metabolic stability,
3. (a) Selva, E.; Beretta, G.; Montanini, N.; Saddler, G. S.; Gastaldo, L.; Ferarri, P.;
Lorenzetti, R.; Landini, P.; Ripamonti, F.; Goldstein, B. P.; Berti, M.; Montanaro,
L.; Denaro, M. J. Antibiot. 1991, 44, 693; (b) Kettenring, J.; Colombo, L.; Ferrari,
P.; Tavecchia, P.; Nebuloni, M.; Vekey, K.; Gallo, G. G.; Selva, E. J. Antibiot. 1991,
44, 702; (c) Selva, E.; Ferrari, P.; Kurz, M.; Tavecchia, P.; Colombo, L.; Stella, S.;
Restelli, E.; Goldstein, B. P.; Ripamonti, F.; Denaro, M. J. Antibiot. 1995, 48, 1039.
bioavailability and protein ligand interactions.27 Compounds 3f
and 3g with electron donating methyl and methoxy substitutions,
respectively, show minimum to moderate antibacterial activity
against all the tested bacterial strains in the range of 12.5–
4.
(a) Hantzsch, A.; Weber, J. H. Ber. Dtsch. Chem. Ges. 1887, 20, 3118; (b) Bauer,
W.; Kühlein, K. In Houben-Weyl’s Methoden der Organischen Chemie; Georg
Thieme Verlag: Stuttgart, New York, 1985; Vol. E85, p 1218; (c) Liebscher, J.
Houben-Weyl’s Methoden der Organischen Chemie In Vol. E8b; Georg Thieme
Verlag: Stuttgart, 1994. Teil 2, pp 1–399.
2
00 lg/mL except 3f against E. coli which shows good inhibition
activity. Moreover, by the introduction of one more phenyl group
in the nitrogen site of thiazole ring (compound 3h) moderate activ-
ity was noted. Compounds (3i, 3j, and 3k) having electron with-
drawing substituent at the phenyl group in C-2 and C-4 of
piperidine ring and one more phenyl group at the nitrogen site of
thiazole ring registered significant bacterial activity (i.e., com-
pound 3i against S. aureus and B. subtilis, 3j against S. typhi and
5.
Sharma, P. K.; Swonhney, S. N.; Gupta, A.; Singh, G. B.; Bani, S. Indian J. Chem.
1998, 37B, 371.
6. Beck, G.; Heitzer, H. U.S. Patent 4,748,243, May 31, 1988.
7.
8.
9.
Osaka, H. U.; Matsubara, N. H.; Kawabe, I. M. U.S. Patent 5,180,833, Jan 19,
993.
Schulze, K.; Richter, F.; Seisheit, R.; Krause, R.; Muhlstadt, M.; Darstellung, Z.;
Vinylsenfölen, C. V. J. Prakt. Chemie. 1980, 322, 629.
Murugan, R.; Scriven, E. F. V. PCT Int. Appl. WO 9,845,279, Oct 15, 1998; Chem.
Abstr. 1998, 129, 302633v.
1
E. coli and 3k against B. subtilis in the range of 6.25–12.5 lg/mL).
Further, the in vitro antifungal activity of all the compounds
(3a–3k) were examined against five pathogenic fungal strains
1
0. Jackson, A.; Heyes, G.; Grayson, J. I.; Clarke, R. U.S. Patent 5,705,652, 1998.
11. Leanna, R. M.; Morton, H. E. PCT Int. Appl. WO 9,616,050,30, 1996; Chem. Abstr.
996, 125, 114603d.
viz. C. neoformans, C. albicans, Rhizopus sp., A. niger and A. flavus.
The obtained MIC values of the tested compounds and standard
are depicted in Table 2. Compounds (3a and 3h) with unsubstitu-
tion at the phenyl group exhibit the activity in the range of 50–
1
1
1
2. Grifantini, M. Curr. Opin. Invest. Drugs 2000, 1, 257.
3. Kempf, D. J.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.;
Flentge, C. A.; Green, B. E.; Fino, L.; Park, C. H.; Kong, X. P.; Wideburg, N. E.;
Saldivar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.;
Plattner, J. J.; Leonard, J. M.; Norbeck, D. W. Proc. Natl. Acad. Sci. U.S.A. 1995, 92,
2
00
the inhibition activity at 12.5
c and 3f/3i were totally inactive (even at 200
l
g/mL except compound 3h against C. albicans, which shows
g/mL. Moreover, compounds 3a,
g/mL) against
l
2484.
3
l
14. Lednicer, D.; Mitscher, L. A.; George, G. I. In Organic Chemistry of Drug Synthesis;
Wiley: New York, 1990; Vol. 4, p 95.
A. flavus, Rhizopus sp. and C. neoformans, respectively. Substitution
of fluoro function in 2,4-diphenylpiperidine moiety of compounds
1
1
5. Rehman, M. Z.; Anwar, C. J.; Ahmad, S. Bull. Korean Chem. Soc. 2005, 26, 1771.
6. Knadler, M. P.; Bergstrom, R. F.; Callaghan, J. T.; Rubin, A. Drug Metab. Dispos.
1986, 14, 175.
3
a and 3h (compound 3b and 3i) has an impact on antifungal activ-
ity. A good inhibition activity was observed for compound 3b
against A. niger (12.5 g/mL) and A. flavus (6.25 g/mL) and com-
pound 3i against C. albicans (12.5 g/mL). A modification of posi-
17. (a)Pharmaceutical Substances; Kleemann, A., Engel, J., Kutscher, B., Reichert, D.,
Eds.; Thieme: Stuttgart, 1999; (b) Rubiralta, M.; Giralt, E.; Diez, A. Piperidine,
Structure, Preparation, Reactivity and Synthetic Applications of Piperidine and its
Derivatives; Elsevier: Amsterdam, 1991.
l
l
l
tion of fluoro function in compounds 3b and 3i (compounds 3c
and 3j) has influence on the antifungal activity. The inhibition
activity of the compound 3c against the tested fungal organism
found to be decreased by three to four folds but against C. neofor-
mans the activity increased by one-fold. Akin to the antibacterial
activity, introduction of methyl or methoxy group in the phenyl
18. (a) Weintraub, P. M.; Sabol, J. S.; Kane, J. M.; Borcherding, D. R. Tetrahedron
2
003, 59, 2953; (b) Kouznetsov, V. V. Khim.-Farm. Zh. 1991, 25, 61–75, Chem.
Abstr. 1991, 115, 158.846h.; (c) Vartanyan, R. S. Khim.-Farm. Zh. 1983, 17, 540–
50, Chem. Abstr. 1983, 99, 53629n.
19. Watson, P. S.; Jiang, B.; Scott, B. Org. Lett. 2000, 2, 3679.
5
20. Aridoss, G.; Amirthaganesan, S.; Kumar, N. A.; Kim, J. T.; Lim, K. T.; Kabilan, S.;
Jeong, Y. T. Bioorg. Med. Chem. Lett. 2008, 18, 6542.
21. Ramachandran, R.; Rani, M.; Kabilan, S. Bioorg. Med. Chem. Lett. 2009, 19, 2819.
rings, minimum to moderate activity was noted (25–200
But, compounds 3f against Rhizopus sp. and 3g against C. neofor-
mans and A. flavus which enhanced the biological activity remark-
l
g/mL).
22. Parthiban, P.; Aridoss, G.; Rathika, P.; Ramkumar, V.; Kabilan, S. Bioorg. Med.
Chem. Lett. 2009, 19, 6981.
2
2
3. Rani, M.; Ramachandran, R.; Kabilan, S. Bioorg. Med. Chem. Lett. 2010, 20, 6637.
4. Baliah, V.; Jeyaraman, R. Indian J. Chem. 1971, 9, 1020.
ably and MIC values found to be 12.5
l
g/mL.
25. Ramachandran, R.; Rani, M.; Kabilan, S. J. Mol. Struct. 2010, 970, 42.
2
6. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Delivery Rev.
997, 23, 3.
In conclusion, a close examination of in vitro antibacterial and
antifungal activities of variously substituted 2-[(2,4-diaryl-3-aza-
bicyclo[3.3.1]nonan-9-ylidene)hydrazono]-4-phenyl-2,3-dihydro-
thiazoles against the tested bacterial and fungal strains provided a
better structure–activity correlation. Of the tested compounds,
1
27. Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem. Soc. Rev. 2008, 37,
320.